Vishal Thakkar, Deputy CFO of Anupam Rasayan India says its proposed Bliss GVS Pharma acquisition will strengthen its pharmaceutical platform across formulations and custom synthesis, while improving access to the US and European markets. The company expects utilisation and margins at Bliss to improve steadily over the next few years.